Medicinal use of cannabis based products and cannabinoids

What you need to know

- Cannabis based products for medicinal use contain cannabinoids derived from the cannabis plant, including ∆⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of THC and CBD. Synthetic cannabinoids for medicinal use typically mimic the effects of specific cannabinoids such as THC.
- THC is the constituent of cannabis that causes the “high,” whereas CBD is not intoxicating at typical doses. THC and CBD have contrasting mechanisms of action and therapeutic indications; THC carries a higher risk of adverse events compared with CBD.
- Rescheduling on 1 November 2018 permits some unlicensed cannabis based products to be prescribed for the first time in the UK, but only by doctors on the relevant Specialist Register of the General Medical Council.
- Indications for treatment, supported by evidence of low to moderate certainty, include chronic pain, some treatment resistant epilepsies, and nausea and vomiting caused by chemotherapy (table 2).
- Non-medicinal CBD products are legal and widely available on the internet and from health food retailers, but they lack quality standards and should not be used for medicinal purposes.

What are the latest developments in regulation, in the UK and internationally?

In the UK, drugs perceived by policy makers to have no medical value and a high risk of misuse, such as MDMA (3,4-methylenedioxy-methamphetamine, common street name “ecstasy”) are placed in Schedule 1 of the Misuse of Drugs Regulations 2001. These drugs cannot be prescribed, and research can only be conducted under a Home Office licence.

On 1 November 2018, unlicensed cannabis based products were moved from Schedule 1 to Schedule 2 in the UK, enabling them to be prescribed for the first time. This amendment of UK legislation affected some but not all products, as some were already listed in Schedule 2 or 4 (table 1). Non-medicinal synthetic cannabinoids (which are found in products such as “Spice”) were not rescheduled and remain in Schedule 1. Cannabidiol (CBD) has minimal risk of misuse⁵ and was never scheduled in the UK.

At the time of writing, in the US cannabis is available for medicinal use in 33 US states and for non-medicinal use in 10 US states, although both remain illegal under federal law. Other recent developments include the legalisation of cannabis for non-medicinal use in Canada on 17 October 2018. The World Health Organization has proposed that cannabis should be rescheduled within international law because of growing evidence of its medicinal applications.⁶

Correspondence to T Freeman t.p.freeman@bath.ac.uk

BMJ: first published as 10.1136/bmj.l1141 on 4 April 2019. Downloaded from http://www.bmj.com/ on 21 September 2023 by guest. Protected by copyright.
What types of product are available and where?

The cannabis plant can produce at least 144 naturally occurring compounds known as cannabinoids. The most widely researched cannabinoids are Δ9-tetrahydrocannabinol (THC) and CBD. THC is the primary constituent of cannabis that causes the “high” whereas CBD is not intoxicating at typical doses. Several different products exist for medicinal use and these differ in THC/CBD profile, formulation, licensed indications, and conditions for prescribing (table 1). See the glossary of terms (box 1) for accepted definitions.

Cannabis based products for medicinal use

Cannabis based products that were previously listed in Schedule 1 can now be prescribed by doctors on the General Medical Council Specialist Register in the UK, on a named patient basis. Currently, general practitioners in the UK cannot prescribe them. These products are not licensed for specific medical indications but are used off licence for medicinal purposes in many countries, and are certified for quality according to good manufacturing practice. Examples include herbal cannabis (floral material from the cannabis plant), The recommended route of administration is through a medical vapouriser device and smoking is currently prohibited under NHS guidance.

Extracts from the cannabis plant (such as cannabis oils containing THC) are also available for oral administration. Some cannabis based products were already available for medicinal use before rescheduling in 2018. Sativex, an oral spray derived from the cannabis plant containing THC and CBD in a 1:1 ratio, is licensed for the treatment of spasticity in multiple sclerosis in 29 countries, including the UK, Israel, Canada, Brazil, and Australia. However, meta-analysis suggests its effectiveness may be limited and it is not recommended by the UK’s National Institute for Health and Care Excellence (NICE) because of poor cost effectiveness. Epidiolex, an oral CBD solution derived from the cannabis plant, was licensed by the US Food and Drug Administration in June 2018 for the treatment of seizures in two rare and severe forms of childhood epilepsy—Lennox-Gastaut syndrome and Dravet syndrome. At the time of writing, an application for the same indication is under review by the European Medicines Agency, and it can currently be prescribed on a named patient basis in the UK.

Synthetic cannabinoids for medicinal use

Dronabinol and nabilone are synthetically produced medicinal products that mimic the effects of THC. Dronabinol has an identical structure to THC, while nabilone has a related structure and is more potent than dronabinol, requiring lower doses to achieve clinical efficacy. Countries including the US, the Netherlands, Germany, Austria, and Croatia have licensed the use of both products. They are licensed for the treatment of weight loss in patients with AIDS and of nausea and vomiting in people receiving chemotherapy who have failed to respond adequately to conventional anti-emetics. Nabilone is licensed in the UK while dronabinol is not licensed but can be prescribed on a named patient basis.

Non-medicinal products

CBD products are also widely available in health food shops and on the internet in the UK and elsewhere (fig 1) and are not scheduled or regulated as medicines. Their THC or psychoactive content is legally controlled not to exceed 0.2% in the EU. As with other herbal remedies, the declared contents of non-medicinal CBD preparations is variable, and often inaccurate, and these products sometimes exceed the legal limit of THC. Moreover, the amount of CBD in these products is typically far lower than in clinical trials (eg, 25 mg in a non-medicinal product versus 150-1500 mg/day in clinical trials). Advise patients that these widely available CBD products lack quality assurance and should not be treated as medicines. Other products include non-medicinal cannabis and non-medicinal synthetic cannabinoids, which are both currently illegal in the UK.

Why and how are cannabis based products and cannabinoids therapeutic (or harmful)?

THC and CBD have contrasting mechanisms of action on the endocannabinoid system, which is widely expressed in the mammalian central and peripheral nervous systems. These actions may account for their therapeutic effects. For example, CBD increased plasma endocannabinoid levels in a clinical trial in schizophrenia, which correlated with the degree of symptom improvement. When taken together with THC, CBD may offset some of the adverse effects of THC, such as memory impairment and paranoia. Therefore, the balance of THC and CBD may contribute to safety as well as therapeutic effects. CBD has an excellent safety profile and is well tolerated, even at high doses.

THC carries an increased risk of adverse events (including serious adverse events). In a systematic review and meta-analysis, cannabinoids (primarily THC) were associated with a fivefold increase in rates of disorientation and dizziness, compared with placebo or active comparators.

What is the evidence underpinning medicinal use of cannabis based products and cannabinoids?

Table 2 summarises evidence from systemic reviews of cannabis based products and cannabinoids for the treatment of chronic pain, multiple sclerosis, treatment resistant epilepsy, and nausea and vomiting associated with chemotherapy. There is less available evidence to estimate the effectiveness of these products for other indications, such as appetite and weight loss associated with HIV/AIDS, Tourette syndrome, anxiety, post-traumatic stress disorder, and schizophrenia.
The limited number of randomised trials for unlicensed cannabis based products is partly attributable to the regulatory challenges of conducting research on drugs in Schedule 1.29 Removing these barriers is an important benefit of rescheduling, which should lead to a stronger evidence base to guide clinical decision making. At the time of writing, the UK National Institute for Health Research (NIHR) has pledged dedicated funding and has called for grant proposals to investigate cannabis based products for medicinal use.

Limitations of current evidence include the inappropriate handling of withdrawals from treatment, selective reporting of outcomes, and inadequate descriptions of randomisation, allocation concealment, and blinding.11 Heterogeneity in the types of product tested, including differences in pharmacokinetics and the balance of THC and CBD content, makes it difficult to establish optimal therapeutic formulations and dosing regimens. More larger and rigorous clinical trials are needed, including further exploration of dose-response and interactions with other medicines.27 For example, both nabiximols (THC) and epi-diol (CBD) may increase the risks of central nervous system depressants such as alcohol.28,29 Epitrochol is metabolised by cytochrome P450 enzymes and may increase the risk of adverse effects from other medicines metabolised by this pathway, such as clobazam and valproate.29

How should doctors manage requests for cannabis based products and cannabinoids? (Box 2)

Box 2: Managing requests for cannabis based products and cannabinoids
Consider
Is this indication supported by evidence from randomised clinical trials? (Table 2)
What is the cannabinoid profile of the medicinal product being requested (THC, CBD, THC/CBD)?
Is this medicinal product available, and who can prescribe it? (Table 1)
 Might this medicinal product interact with other prescribed drugs? Are specific considerations necessary for young people, children and babies, older people, people with mental health problems, people with a learning disability, pregnant women, and women who are breastfeeding? If a prescription is not offered, might this patient seek or use a non-medical product lacking safety and quality assurance?

Guidelines are currently being prepared by NICE, which will initially focus on the indications listed in Table 2. Interim guidance from England’s Chief Medical Officer states that unlicensed cannabis based products can only be prescribed by doctors on the General Medical Council Specialist Register.30 The same guidance also stipulates that doctors should prescribe products only for disorders within their specialty; when there is clear published evidence or UK guidelines to support treatment; when clinical need cannot be met by a licensed medicine; and when established treatment options have been exhausted. Additional guidance has been provided by the Royal College of General Practitioners17 and NHS England.18 Within this framework, specialists in the UK will need authorisation from their medical director and agreement from the multidisciplinary team, using existing protocols on controlled drugs. Therefore, use of unlicensed cannabis based products in the UK may be limited initially, even in specialist settings. Active, compassionate, and fully informed engagement with patients requesting treatment remains important, and questions to consider are given in Box 2. As this is a rapidly evolving field, seek confirmation from the relevant statutory authorities before changing practice.

Education into practice
To what extent might it be stigmatising for a patient to request and use a cannabis based product, and how can this be managed?
Are patients fully aware of the difference between medicinal and non-medicinal products, their legal status, and the risk of harm or prosecution associated with them?
How can I record and share information from my practice on requests for, uses of, and responses to cannabis based products to ensure that future guidelines and guidance better meet the needs of patients?

How this article was created
We used the most up to date and relevant information available to us from systematic reviews, meta-analyses, and key clinical trials. Summary statistics and grading of evidence were obtained from systematic reviews for indications included in forthcoming NICE guidelines. We referred to NICE, the Department for Health & Social Care, NHS England, the UK Home Office, and the Advisory Council for the Misuse of Drugs (ACMD). We discussed our article with clinicians, researchers, and patients.

How patients were involved in the creation of this article
We discussed our article with patients who had health conditions for which there is evidence that cannabis based products or cannabinoids may be effective. We conducted interviews with them asking what they thought would be helpful for patients and clinicians to learn from this article. We showed them drafts of this article and invited them to provide feedback which was incorporated into subsequent versions of the article. On the basis of this feedback, we adapted the structure of the article such that recent policy developments were presented first. We expanded our discussion of the differences between medicinal products and health food supplements, and added a new table to provide an accessible overview of these different products. We highlighted that some patients may seek unlicensed or illegal products if they are unavailable on prescription, and that requesting cannabis based products from a doctor and using them could be stigmatising.

Provenance: commissioned, peer reviewed.
Competing interests The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: TPF was funded by a senior academic fellowship from the Society for the Study of Addiction (SSA). MAPB is funded by a UCL Excellence Fellowship. MAPB, SFG, and CH are supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. The views expressed here are those of the authors, and do not reflect those of the SSA, the University of Bath, UCL, or NIHR. The funders had no role in the planning, researching, or writing of this report or in the decision to submit it for publication. Further details of The BMJ policy on financial interests is here: https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/declaration-competing-interests
Contributorship statement and guarantor TPF had the idea for this article and wrote the first draft. All authors provided substantial contributions to the design of the work, CH, SFG, and MAPB wrote additional sections. Two anonymous patients suggested additional changes. All authors revised the article and approved the final version. As the guarantor, TPF affirms that the manuscript provides an honest, accurate, and transparent account of the issues covered, that there are no important omissions, and that there are no discrepancies between what was planned and the final version. All authors accept full responsibility for the work and the decision to publish.

Acknowledgments We thank two patients for their feedback on previous versions of this article. Both preferred to stay anonymous.

1 The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018 http://www.legislation.gov.uk/uksi/2018/1055/pdfs/uksi_20181055_en.pdf
2 Pavlovic R, Nenna G, Calvi L, et al. Quality traits of ‘cannabidiol oils’: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules 2018;23:1230. 10.3390/molecules23051230 29783790
3 Nesseink RJ, Rigter S, Koster MW, Brunt TM. Potency trends of Δ-9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction 2016;110:1941-50. 10.1111/add.12982.26234170
4 Kalk NJ, Boyd A, Strang J, Finch E. Spice and all things nasty: the challenge of synthetic cannabinoids. BMJ 2016;355:i6639. 10.1136/bmj.i6639.27772737
5 Schiedel KA, Saxo I, Sivnik B, et al. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav 2018;88:162-71. 10.1016/j.yebeh.2018.07.027.30286443
6 Mayer S. WHO proposes rescheduling cannabis to allow medical applications. BMJ 2019 https://www.bmj.com/content/364/bmj.i787.
7 Hanuš LD, Meyer SM, Muhoz E, Taglialetela-Scafati O, Appignani G. Phyto cannabinoids: a unified critical inventory. Nat Prod Rep 2016;33:1357-92. 10.1039/C6NP00747F.27722075
8 European Monitoring Centre for Drugs and Drug Addiction. Cannabis legislation in Europe: an overview. Publications Office of the European Union, Luxembourg. 2016. http://www.emcdda.europa.eu/publications/adhoc/cannabis-legislation-europe_en
9 Abrams DI, Vozze HP, Shade SB, Jay C, Kelly ME, Barowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007;82:572-8. 10.1038/jc.2007.82.17429250
10 Department of Health & Social Care. Cannabis-based products for medical use. London. 2018. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/753444/letter-with-guidance-on-cannabis-based-products-for-medical-use.pdf
11 Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015;313:2465-73. 10.1001/jama.2015.6358.26103930
12 National Institute for Health and Care Excellence. Do No Do Recommendations: Sativex. London, 2014. https://www.nice.org.uk/donotdo/do-not-offer-sativex-to-treat-spasticity-in-people-with-MS-because-it-is-not-a-cost-effective-treatment.
13 Hazekamp A. The trouble with CBD oil. Nat Rev Neurosci 2018;19:199-215. 10.1038/sj.nrn.2016.28.27722075
14 Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: a naturalistic study; naturalistic study [corrected]. Br J Psychiatry 2010;197:285-90. 10.1192/bjp.bp.109.077533.20884851
15 Shinnick A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paroxysmal symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2015;29:19-27. 10.1177/0269881115548010.20428468
16 Taylor LR, Giral G, Blairay G, Taya B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabin in healthy subjects. CNS Drugs 2018;32:1053-67. 10.1007/s40263-018-0578-5.30374683
17 Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 2018;159:1932-54. 10.1097/j.pain.0000000000001293.29847469
18 Morgan CJ, Schiatter G, Freeman TP, Curran HV. Impact of cannabinol on the acute memory and psychotomimetic effects of smoked cannabis: a naturalistic study; naturalistic study [corrected]. Br J Psychiatry 2010;197:285-90. 10.1192/bjp.bp.109.077533.20884851
19 Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paroxysmal symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2015;29:19-27. 10.1177/0269881115548010.20428468
20 Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabinol on the acute memory and psychotomimetic effects of smoked cannabis: a naturalistic study; naturalistic study [corrected]. Br J Psychiatry 2010;197:285-90. 10.1192/bjp.bp.109.077533.20884851
21 Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THCN-elicited paroxysmal symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 2015;29:19-27. 10.1177/0269881115548010.20428468
22 Taylor LR, Giral G, Blairay G, Taya B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabin in healthy subjects. CNS Drugs 2018;32:1053-67. 10.1007/s40263-018-0578-5.30374683
23 Stockings E, Campbell G, Hall WD, et al. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain 2018;159:1932-54. 10.1097/j.pain.0000000000001293.29847469
24 Stockings E, Zajic D, Campbell G, et al. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 2018;89:741-53. 10.1136/jnnp-2017-317168.295111052
25 Guyatt GH, Osman AD, Vlot GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. 10.1136/bmj.39489.470347.AD.18436948
26 The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. National Academies of Sciences E, Medicine. National Academies Press 2017.
27 European Monitoring Centre for Drugs and Drug Addiction. Medical use of cannabis and cannabinoids: questions and answers for policymaking. Publications Office of the European Union, Luxembourg. 2018. http://www.emcdda.europa.eu/system/files/publications/10171/20185584_TD0618186ENN_PDF.pdf
28 Freeman TP, Motla MA, Nalt JC, Nut DJ, Tunbridge EM, Young AH. Restrictions on drugs with medical value: Moving beyond stalemate. J Psychopharmacol 2018;32:1053-5. 10.1177/0269881117806903.30278146
29 Highlights of prescribing information: EPIDIOLEX. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
30 emc. Nabilone 1mg capsules. 2014. https://www.medicines.org.uk/emc/product/6176/smpc.
31 Highlights of prescribing information: EPIDIOLEX. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
32 NHS England. Cannabis-based products for medicinal use. https://www.england.nhs.uk/commpost/6176/smpc.
33 Royal College of General Practitioners. Cannabis-based medicines: an interim desktop guide 2018. https://www.rcgp.org.uk/clinical-and-research-resources/a-to-a-clinical-resources/cannabis-based-medications.aspx
34 NHS England. Cannabis-based products for medicinal use. https://www.england.nhs.uk/mmedicines/support-for-prescribers/cannabis-based-products-for-medical-use/
35 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
## Tables

### Table 1 | An overview of cannabis based products and cannabinoids

| Example | Medicinal products | Synthetic cannabinoids for medicinal use | Non-medicinal products | Non-medicinal cannabinoids |
|---------|--------------------|------------------------------------------|------------------------|---------------------------|
|         | Cannabis based products for medicinal use | THC +/- CBD | THC +/- CBD ratio 1:1 | CBD | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |
| Bedrocan | THC +/- CBD | THC-7 CBD ratio 1:1 | CBD | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |
| Tilray | THC-7 CBD ratio 1:1 | CBD | THC | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |
| Sativex | THC-7 CBD ratio 1:1 | CBD | THC | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |
| Epidiolex | THC-7 CBD ratio 1:1 | CBD | THC | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |
| Dranabinol | THC-7 CBD ratio 1:1 | CBD | THC | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |
| Nabilone | THC-7 CBD ratio 1:1 | CBD | THC | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |
| CBD oil | THC-7 CBD ratio 1:1 | CBD | THC | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |
| White Widow | THC-7 CBD ratio 1:1 | CBD | THC | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |
| Spice | THC-7 CBD ratio 1:1 | CBD | THC | THC | THC | High CBD, low THC | High THC, low CBD | Synthetic cannabinoid receptor agonists |

### Quality standards

- **Formulation**
  - Herbal cannabis
  - Oil
  - Oromucosal spray
  - Oral solution
  - Capsule or liquid
  - Capsule
  - Variied; capsule and oil
  - Varied; herbal cannabis
  - Herbal, liquid, or powder

- **Licensed indications (UK)**
  - None
  - None
  - Multiple sclerosis
  - None
  - None
  - Chemotherapy induced nausea and vomiting
  - Not medicinal products

- **Quality standards**
  - Good manufacturing practice
  - Good manufacturing practice
  - Good manufacturing practice
  - Good manufacturing practice
  - Good manufacturing practice
  - Good manufacturing practice
  - No quality assurance

- **Affected by rescheduling (UK) on 1 November 2018?**
  - Yes
  - Yes
  - No
  - No
  - No
  - No
  - No

- **Pre-amendment Schedule (UK)**
  - 1
  - 1
  - 4
  - Not scheduled
  - 2
  - 2
  - Not scheduled (if THC does not exceed 0.2%)

- **Post-amendment Schedule (UK)**
  - 2
  - 2
  - 4
  - Not scheduled
  - 2
  - 2
  - Not scheduled (if THC does not exceed 0.2%)

- **Can be prescribed in the UK?**
  - Doctors on General Medical Council specialist register; named patient basis
  - Doctors on General Medical Council specialist register; named patient basis
  - Specialist doctors with expertise in treating multiple sclerosis
  - No restrictions on prescribing; named patient basis. Likely to be a specialist prescribing due to the proposed indications
  - No restrictions on prescribing; named patient basis
  - No restrictions on prescribing; named patient basis
  - Preferably administered in a hospital setting. GPs may prescribe once treatment initiated

- **No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe**
| Indication                        | Number of studies (participants) | Primary products tested | Comparator | Outcome                                        | Summary estimate (95% confidence interval) | GRADE certainty rating |
|----------------------------------|----------------------------------|-------------------------|------------|-----------------------------------------------|---------------------------------------------|------------------------|
| Chronic pain                     | 9 (1734)                         | Sativex (THC+CBD)       | Placebo    | 30% reduction in pain                         | Odds ratio: 1.46 (1.16 to 1.84). More effective than placebo | ⨁⨁⨁◯ Moderate          |
| Multiple sclerosis               | 5 (1244)                         | Sativex (THC+CBD)       | Placebo    | Ashworth spasticity scale                     | Weighted mean difference: -0.12 (-0.24 to 0.01). Not more effective than placebo | ⨁⨁⨁◯ Moderate          |
| Treatment resistant epilepsy     | 2 (291)                          | Epidiolex (CBD)         | Placebo    | 50% reduction in seizure frequency            | Relative risk: 1.74 (1.24 to 2.43). More effective than placebo | ⨁◯◯◯ Low               |
| Nausea and vomiting due to      | 3 (102)                          | Dronabinol (THC)        | Placebo    | Complete response in nausea and vomiting      | Odds ratio: 3.82 (1.55 to 9.42). More effective than placebo | ⨁◯◯◯ Low               |

Grading of recommendations, assessment, development, and evaluations (GRADE):

- ⨁⨁⨁⨁ High, the authors have a lot of confidence that the true effect is similar to the estimated effect.
- ⨁⨁⨁◯ Moderate, the authors believe that the true effect is probably close to the estimated effect.
- ⨁◯◯◯ Low, the true effect might be markedly different from the estimated effect.
- ⨁◯◯◯◯ Very low, the true effect is probably markedly different from the estimated effect.
Figure

Fig 1 Non medicinal CBD products are widely available